What pharma companies do patient groups think are best in HIV/AIDS?

Above is an animated presentation about PatientView’s latest report (optimised for Internet Explorer only). Please click on the ‘Forward’ arrow. The Prezi may take 30 seconds to load, so please be patient. Once loaded, to view in fullscreen, click on ‘More’, and then on ‘Fullscreen’.

In June 2011, the United Nations issued a political declaration aimed at intensifying the efforts of researchers to find new ways to tackle HIV/AIDS with affordable treatments. And in July 2011, the Geneva-based International AIDS Society (IAS) announced a global scientific strategy, ‘Towards an HIV Cure’, that intends to define “scientific priorities which must be addressed by future research to tackle HIV persistence in patients undergoing antiretroviral therapy. In light of the UN declaration and the IAS initiative, PatientView decided to find out WHAT PATIENT GROUPS THINK OF INDUSTRY’S EFFORTS IN HIV/AIDS, AND WHETHER IT COULD IMPROVE

Background: Why this report?

In August-September 2011, PatientView conducted a global online survey of some 180 patient groups with an interest in HIV/AIDS. Groups were asked to:

l Specify whether they are familiar, and have partnered with, 20 pharma companies and 32 biotech companies with an interest in HIV/AIDS.

l Identify which of the 20 pharma companies are best across 7 different indicators that measure the effectiveness of industry HIV/AIDS R&D.

l Provide strategic directions for improving industry’s HIV/AIDS R&D efforts.

The seven indicators by which the HIV/AIDS patient groups measured the effectiveness of pharma company HIV/AIDS R&D and ensuring access to medicines:

1. Being best at providing people with HIV/AIDS with ‘special access’ to drugs (after good results have been obtained in clinical trial, but before the drugs have been approved by regulators).

2. Being best at managing R&D effectively (with the direct aim of ensuring newest medications are not so expensively priced).

3. Being best at providing compassionate use of HIV/AIDS drugs to people who would otherwise not be able to afford to pay for them.

4. Being best at tackling major clinical questions that people living with HIV/AIDS want answered about HIV/AIDS drugs (such as reducing side-effects, or making drugs easier to take).

5. Being best at undertaking clinical research among people truly representative of the population of individuals who are living with HIV/AIDS.

6. Being best at keeping patients in clinical trials well informed about the processes in which they are partaking.

7. Being most innovative in the search for a cure for HIV/AIDS.       

The companies assessed in this report

The 20 pharma companies (though some companies are related to one another, each was assessed by patient groups on individual merit):

l Abbott l Boehringer Ingelheim l Bristol Myers Squibb (BMS) l Genentech l Gilead l GSK l Janssen l Johnson & Johnson l Merck & Co l Merck Ag  l Merck Frosst l Novartis l Pfizer l Roche (Hoffmann-La Roche) l Sanofi Pasteur l Sanofi-Aventis l Shionogi l Takeda l Tibotec l ViiV Healthcare

The 32 biotech companies:

l Agouron Pharmaceuticals l Achillion l Ardea Biosciences l Argos Therapeutics l Auxilium Pharma l Avexa l Bavarian Nordic l Bionor Pharma l Biotron l Chimerix l Cytheris l Enzo Biotech l Esteve Pharmaceuticals l FIT-Biotech l Genetic Immunity l GeoVax l Idenix Pharmaceuticals l Inovio l Peregrine Pharmaceuticals l Pharmasset l Progenics l RFS Pharma l Salix Pharmaceuticals l Sangamo Biosciences l SEEK l TaiMed l Tarix Pharmaceuticals l Theratechnologies l Tobira Therapeutics l Trimeris l Virostatics l VIRxSYS

Where are the patient groups based?

180 patient groups with an interest in HIV/AIDS from 41 countries contributed to the study. Senior executives from 50 of the 180 groups provided views on pharma rankings.


The HIV/AIDS patient groups identify strategies through which pharma HIV/R&D R&D amd access to medicines might be improved.

For more about this report, email report@patient-view.com, or telephone 0044-(0)1547-520-965 (contacts are Alexandra Wyke and/or Clive Nead)